Study on the Treatment of Differentiated Thyroid Carcinoma With Anlotinib
Status:
Recruiting
Trial end date:
2022-12-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of anlotinib in patients with locally
advanced or metastatic differentiated thyroid cancer resistant to iodine therapy.